Alseres Pharmaceuticals Inc (ALSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 46 | 94 | 114 | 27 | 28 |
| Marketable Securities | 148 | 185 | 207 | 24 | 26 |
| TOTAL | $220 | $305 | $325 | $75 | $85 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 59 | 60 | 61 | 62 | 63 |
| TOTAL | $59 | $60 | $61 | $62 | $63 |
| Total Assets | $279 | $364 | $386 | $137 | $148 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,604 | 1,541 | 1,556 | 2,183 | 2,152 |
| Other current liabilities | 10 | 12 | 13 | N/A | N/A |
| TOTAL | $1,811 | $1,690 | $1,648 | $10,199 | $9,828 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,297 | N/A | 7,820 | N/A | N/A |
| Deferred Revenues | 74 | 74 | 74 | 74 | 74 |
| Other Non-Current Liabilities | 445 | 8,568 | 434 | 16,419 | 16,414 |
| TOTAL | $9,847 | $9,693 | $9,397 | $17,580 | $17,593 |
| Total Liabilities | $11,658 | $11,383 | $11,045 | $27,779 | $27,421 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6 | 6 | 6 | 6 | 6 |
| Common Shares | 306 | 306 | 306 | 306 | 306 |
| Retained earnings | -200,288 | -199,967 | -199,635 | -199,874 | -199,511 |
| Other shareholders' equity | -50 | -14 | 7 | -35 | -33 |
| TOTAL | $-11,379 | $-11,018 | $-10,660 | $-27,642 | $-27,273 |
| Total Liabilities And Equity | $279 | $365 | $386 | $137 | $148 |